Dr. Ahmed H. Hussein, PhD
Department of Pharmaceutics and Drug Industry
Faculty of Pharmacy , Kufa University
Cell phone # : 00964-7809421523
E-Mail: ahmd_3h@yahoo.com , ahmedh.moses@uokufa.edu.iq
•
•
•
.1
.2
.3
.4
.5
Generic
.6SDI ,NDI
.7
.8
•
•
•
•
•
•



-
-
•
•
•
•
•
•
•
•
•
•-RP-
-RP
•
•
Pharco Corporation)
•
Pharco B International)
•
•
•
•
•--------
•
•
•
•
•
•–
•
•
•
•
•
•-
•
•------
•
•
•
•
•
•
•
•
•
•
•
•
GMP
•
)GENERICS
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
-
-
•
•
•
•
•
•
•
•
•
•
•
•
Global top market growth
Source: IMS World Review Analyst
​ ​2011 ​ ​ ​ 2009​ ​
Country​ Rank​ $ (Mill)​ Growth
(%)​
Rank $ (Mill)​ Growth
(%)​
United States ​ 1 322,290 3 1 301​,095 6
Japan ​ 2 111,642 16​ 2 89,865​ 17​
China ​ 3 66,805​ 22 3 45,261​ 24
Germany​ 4 44,​916 7 4 41,​287 -2​
France ​ 5 41,197​ 6​ 5 40,452 -5
Brazil ​ 6 28,465 ​ 23​ 10 17,629 8
Italy 7 28,357 ​ 7​ 6 27,​085 -1​
Spain ​ 8 22,679​ 2 7 22,722 1
Canada ​ 9 22,294 ​ 3​ 9 19,143 0
United
Kingdom ​​
10 21,564 ​ 6​ 8 19,​830 -11
•
•
•
•
•
•
•
•
•
•
•
•
•
SDI
•
)ISO(
•SDI
•SDI
•
•
•
•
•
•ISO900 2008
•
NDI
•NDISDI
•NDI
•
Marchesin
Group
•
•
NDI
•
•
Bram
•EKSEN
•
•
•
•
•
.
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
S.D.I)




GM

•
•
•
•
•----
•
•
•
:
•
•
.
•
•
-
•
•
•
•
•
•
•
•
-
• most highly valuable five molecules in Iraq for 2012
Trastuzumab inj( HER2)( Recombinant )
440mg/Vial (HER2
• tetanus vaccine )
• Deferasirox dispersible 500mg
Tablet $ 65,322,936Imatinib as mesylate (Protein –
Tyrosine kinase inhibitor) 100mg
Capsule $ 62,701,824Recombinant Factor VIII, 500
IU $ 55,231,513
•-
The top 15 therapeutic areas make up $379B of the total $750B
total global drug market.
The top therapeutic areas in 2012
•
•
•
•
•
•
•
.2008May“Pharmaceutical Companies50s Top’on the worldAnnual Reportth9Our„ExecutivePharmaceutical
Pfizer45.18.1
18
GlaxoSmithKline39.36.416
Novartis38.16.416.8
Aventis-Sanofi37.46.517.3
AstraZeneca25.75.119.8
Johnson & Johnson23.35.3
22.7
MSD Sharp & Dohme22.64.9
21.6
La Roche-Hoffmann16.96.739.6
Wyeth15.93.1
19.4
and CompanyEli Lilly14.83.5
23.6
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•Pharmaceutical Research and Manufacturers
of America (PhRMA)
Priority Watch List
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•------
•
•
•
•
لصناعة الدوائية في العراق   الواقع  التحديات والمستقبل     د احمد هاشم  حسين

لصناعة الدوائية في العراق الواقع التحديات والمستقبل د احمد هاشم حسين